Oligonucleotide CDMO Global Market Report 2025, with Profiles of Bachem, Thermo Fisher Scientific, Agilent Technologies, EUROAPI, ST Pharm, Wuxi Apptec, Maravai Lifesciences, Biospring and More

Market Overview - The global oligonucleotide CDMO market is projected to grow from USD 2.51 billion in 2024 to USD 6.73 billion in 2029, with a CAGR of 21.8% during the forecast period [3] - Key drivers include the increasing focus on novel oligo-based drugs and growing outsourcing to CDMOs, supported by FDA approvals such as Qalsody (tofersen) for ALS treatment in April 2023 [4] - The Asia Pacific region is the fastest-growing market due to rapid biopharmaceutical industry growth and cost advantages in labor and production [7] Market Segmentation - The contract manufacturing segment held the largest market share in 2023, driven by CDMOs' expertise in reducing production timelines and improving scalability [5] - Pharmaceutical and biotechnology companies are the largest end-user segment, relying on CDMOs for complex oligonucleotide synthesis and regulatory compliance [6] - Applications include therapeutic, research, and diagnostic uses, with therapeutic applications driving significant growth due to increasing demand for oligonucleotide-based drugs [23] Key Players - Major companies profiled in the report include Bachem, Thermo Fisher Scientific, Agilent Technologies, Wuxi Apptec, Maravai Lifesciences, and Lonza [9][23] - Other notable players include Eurofins Scientific, Danaher, GenScript, Syngene International, and ST Pharm [9][23] Market Dynamics - Drivers: Growing focus on oligo-based therapeutics, advantages of outsourcing to CDMOs, and increasing use of oligos in CRISPR-Cas9 applications [4][13] - Restraints: Complexities associated with oligonucleotide manufacturing [12] - Opportunities: Increasing use of oligos in CRISPR-Cas9 applications and advancements in precision medicine [13][17] - Challenges: Lack of sustainable and eco-friendly supply chains [14] Regional Insights - North America and Asia Pacific are key regions, with Asia Pacific experiencing rapid growth due to cost advantages and increasing biopharmaceutical innovation [7][17] Technological and Market Developments - The report highlights upcoming technologies, R&D activities, and market diversification strategies, including new services and untapped geographies [16] - Competitive assessment includes market shares, growth strategies, and service offerings of leading players [16]